LT2550966T - Dabigatrano amidoksimo karboksirūgšties esteriai, kaip provaistai, ir jų panaudojimas kaip vaistų - Google Patents

Dabigatrano amidoksimo karboksirūgšties esteriai, kaip provaistai, ir jų panaudojimas kaip vaistų

Info

Publication number
LT2550966T
LT2550966T LTEP11175230.9T LT11175230T LT2550966T LT 2550966 T LT2550966 T LT 2550966T LT 11175230 T LT11175230 T LT 11175230T LT 2550966 T LT2550966 T LT 2550966T
Authority
LT
Lithuania
Prior art keywords
dabigatran
prodrugs
medicament
carboxylic acid
acid esters
Prior art date
Application number
LTEP11175230.9T
Other languages
English (en)
Inventor
Prof. Dr. Bernd Clement
Dr. Joscha Kotthaus
JĆ¼rke Kotthaus
Dennis Dr. Schade
Original Assignee
Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg filed Critical Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg
Publication of LT2550966T publication Critical patent/LT2550966T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
LTEP11175230.9T 2011-07-25 2011-07-25 Dabigatrano amidoksimo karboksirūgšties esteriai, kaip provaistai, ir jų panaudojimas kaip vaistų LT2550966T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11175230.9A EP2550966B1 (de) 2011-07-25 2011-07-25 Dabigatran-Amidoximsäureesters als Prodrugs und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
LT2550966T true LT2550966T (lt) 2017-01-25

Family

ID=46466528

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP11175230.9T LT2550966T (lt) 2011-07-25 2011-07-25 Dabigatrano amidoksimo karboksirūgšties esteriai, kaip provaistai, ir jų panaudojimas kaip vaistų

Country Status (20)

Country Link
US (1) US8853245B2 (lt)
EP (2) EP2550966B1 (lt)
JP (1) JP2014521619A (lt)
KR (1) KR20140049021A (lt)
CN (1) CN103945845A (lt)
AU (1) AU2012289112B2 (lt)
BR (1) BR112014001970A2 (lt)
CA (1) CA2842304A1 (lt)
CY (1) CY1118294T1 (lt)
DK (1) DK2550966T3 (lt)
ES (1) ES2611610T3 (lt)
HK (1) HK1201738A1 (lt)
HR (1) HRP20161675T1 (lt)
HU (1) HUE032862T2 (lt)
LT (1) LT2550966T (lt)
PL (1) PL2550966T3 (lt)
PT (1) PT2550966T (lt)
RU (1) RU2014106866A (lt)
SI (1) SI2550966T1 (lt)
WO (1) WO2013013946A1 (lt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040045742A1 (en) * 2001-04-10 2004-03-11 Halliburton Energy Services, Inc. Force-balanced roller-cone bits, systems, drilling methods, and design methods
CN107027308A (zh) * 2014-08-06 2017-08-08 四川海思科制药有限公司 一种达比加群硫酯衍生物及其制备方法和在药学上的用途
CN106470987A (zh) * 2014-08-06 2017-03-01 四川海思科制药有限公司 一种达比加群酯衍生物及其制备方法和在药学上的用途
DE102016102887A1 (de) * 2016-02-18 2017-08-24 Develco Pharma Schweiz Ag Orale Darreichungsform eines Dabigatran-Prodrugs zur Behandlung von Krankheiten
CN110448557A (zh) * 2019-09-05 2019-11-15 黄筱茜 抗凝血药达比加群酯的新药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
DE10235639A1 (de) * 2002-08-02 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10341043A1 (de) 2003-09-03 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue oral zu applizierende Darreichungsform für 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester und dessen Salze
AR062057A1 (es) * 2006-07-17 2008-10-15 Boehringer Ingelheim Int Uso de los inhibidores directos de la trombina
DE102008007440A1 (de) * 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Aminosäurederivate als Arzneistoffe
DE102008007381A1 (de) * 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten
MX2011004796A (es) * 2008-11-11 2011-05-30 Boehringer Ingelheim Int Metodo para tratar o prevenir la trombosis usando etexilato de diabigatran o una sal del mismio con una eficacia mejorada sobre la terapia con warfarina convencional.
AU2009315731A1 (en) * 2008-11-11 2010-05-20 Boehringer Ingelheim International Gmbh Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
DE102009004204A1 (de) * 2009-01-09 2010-07-15 Christian-Albrechts-Universität Zu Kiel Verfahren zur verbesserten Bioaktivierung von Arzneistoffen

Also Published As

Publication number Publication date
DK2550966T3 (en) 2017-02-06
HUE032862T2 (en) 2017-11-28
RU2014106866A (ru) 2015-08-27
CA2842304A1 (en) 2013-01-31
CY1118294T1 (el) 2017-06-28
BR112014001970A2 (pt) 2017-02-21
HRP20161675T1 (hr) 2017-02-24
AU2012289112A1 (en) 2014-02-13
EP2773347B1 (de) 2017-09-13
PL2550966T3 (pl) 2017-03-31
EP2773347A1 (de) 2014-09-10
KR20140049021A (ko) 2014-04-24
SI2550966T1 (sl) 2017-01-31
JP2014521619A (ja) 2014-08-28
PT2550966T (pt) 2017-01-31
EP2550966B1 (de) 2016-10-19
US20130030023A1 (en) 2013-01-31
EP2550966A1 (de) 2013-01-30
CN103945845A (zh) 2014-07-23
WO2013013946A1 (de) 2013-01-31
ES2611610T3 (es) 2017-05-09
HK1201738A1 (en) 2015-09-11
AU2012289112B2 (en) 2017-01-05
US8853245B2 (en) 2014-10-07

Similar Documents

Publication Publication Date Title
IL236376B (en) Acespentanoic acid ethyl ester for use as a drug Methods to reduce the risk of death due to a cardiovascular event
EP2797600A4 (en) IMPROVED COMPOSITIONS AND METHODS OF DISTRIBUTING OMEPRAZOLE AND ACETYL SALICYLIC ACID
HK1201122A1 (en) 6-amino-2-substituted-5-vinylsilylpyrimidine-4-carboxylic acids and esters and 4-amino-6-substituted-3-vinylsilylpyridine-2-carboxylic acids and esters as herbicides 6--2--5--4- 4-- 6--3--2-
LT2785205T (lt) Priešmikrobinis aldehidų, organinių rūgščių ir organinių rūgščių esterių mišinys
IL233413A0 (en) Methods for producing fincol esters of 4-chloro-2-fluoro-3-converted-phenylboronic acid and methods for using them
EP2788356A4 (en) SULFATESTER FROM NORIBOGAIN
ZA201401746B (en) Use and agrochemical composition of carboxylic acid dibutylamides
ZA201303357B (en) Ketocarboxylic acids, ketocarboxylic esters, methods of manufacture and uses thereof
ZA201400087B (en) Fluorination of acrylate esters and derivatives
HK1197671A1 (zh) 製造 -氟代- -甲基- -喹啉- -基甲基-吲哚基 -乙酸酯的步驟
SG2014012587A (en) Process for preparation of methacrylic acid and methacrylic acid esters
HK1201738A1 (en) Dabigatran amidoxime acid esters as prodrugs and use thereof as pharmaceuticals
EP2920144A4 (en) MEK INHIBITORS IN THE FORM OF CARBOXYLIC ACID ESTER PRODRUGS
SI2550963T1 (sl) Estri amidoksim karboksilne kisline pentamidina kot predzdravila in njihova uporaba kot zdravila
SG2014012637A (en) Process for preparation of methacrylic acid and methacrylic acid ester
SG2014012561A (en) Process for preparation of methacrylic acid and methacrylic acid esters
EP2684864A4 (en) PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 1-AMINO-2-VINYLCYCLOPROPANECARBOXYLIC ACID ESTER
TH148772B (th) กรรมวิธีสำหรับการเตรียมกรดเมแธคริลิคและเอสเทอร์ของกรดเมแธคริลิค